06/23/22 11:00 AMNasdaq : ATHE clinical trialAlterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in ItalyAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the Italian MedicinesRHEA-AIneutral
06/02/22 8:00 AMNasdaq : ATHE clinical trialAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System AtrophyAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing diseaseRHEA-AIneutral
04/27/22 7:40 AMNasdaq : ATHE clinical trialAlterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United KingdomAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United Kingdom Medicines &RHEA-AIneutral
04/06/22 9:34 PMNasdaq : ATHE Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual MeetingAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatmentsRHEA-AIneutral
03/07/22 7:59 AMNasdaq : ATHE conferencesAlterity Therapeutics to Present at the 34th Annual Roth ConferenceAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D.,RHEA-AIneutral
01/28/22 7:08 AMNasdaq : ATHE Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's DiseaseAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of MultipleRHEA-AIneutral
01/27/22 7:45 AMNasdaq : ATHE Appendix 4C - Q2 FY22 Quarterly Cash Flow ReportHighlights:NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH434 to treat neurodegenerative diseases New US composition of matter patent secures exclusivity for aRHEA-AIneutral
01/06/22 7:30 AMNasdaq : ATHE Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer'sAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States PatentRHEA-AIvery positive
01/05/22 7:45 AMNasdaq : ATHE conferencesAlterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief ExecutiveRHEA-AIneutral
12/14/21 7:25 AMNasdaq : ATHE clinical trialAlterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical TrialAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that the New Zealand Medicines and MedicalRHEA-AIneutral